key: cord-0877632-qkxxg9u0
authors: Runge, John S.; Bardhi, Redina; Xia, Yang; Jairath, Neil K.; Wilcox, Ryan A.; Tsoi, Lam C.; Tejasvi, Trilokraj
title: Clinical outcomes in a cohort of patients with cutaneous T cell lymphoma and COVID-19
date: 2022-05-03
journal: JAAD Int
DOI: 10.1016/j.jdin.2022.04.008
sha: e73ed519b317f4ec3340456fee416445eee0cde7
doc_id: 877632
cord_uid: qkxxg9u0

nan

Patients with malignancies are at risk of poor outcomes from COVID-19. 1 In particular, the 34 death rate of patients with hematologic malignancies is reported to be 14% within one month 35 of COVID-19 diagnosis. 2 It remains unclear if patients with cutaneous lymphomas are at 36 comparable risk. One study reported that patients with cutaneous lymphomas infected with 37 COVID-19 have the same susceptibility and outcomes as healthy patients. 3 However, advanced 38 age and long-term immunosuppressive therapy may place patients with cutaneous lymphomas 39 at risk for life threatening complications. 4 We aimed to assess the impact of COVID-19 infection 40 on patients with primary cutaneous T cell lymphomas (CTCLs) at our institution. 41

Our study was conducted with approval of the Institutional Review Board at the University of 43

Michigan. We retrospectively reviewed patient records for individuals diagnosed with CTCL at 44

Michigan Medicine from 2010-2022. Patients deceased prior to 2/1/2020 were excluded. In our 45 cohort of 384 cases of cutaneous lymphoma seen at our health system since 1/1/2010, we 46 identified 24 unique patients with CTCL that tested positive for COVID-19. To understand the 47 risk factors for patients that tested positive for COVID-19, we performed a retrospective 48 analysis for lymphoma-related disease history. 49 50 A summary of patient demographics and CTCL history at the time of COVID-19 infection is 51 provided in Table 1 . Our cohort includes 13 males and 12 females with a median age of 57.08 52 (Range 18-88). Diagnoses ranged from lymphomatoid papulosis to mycosis fungoides with large 53 cell transformation, leukemic involvement, or erythroderma (Sezary syndrome). The majority of 54 cases were patients with stage IA or IB disease (13 cases, 52%). A smaller subset had stage II-IV 55 disease (See Table 1 

Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A 73

Systematic Review and Meta-Analysis